A detailed history of Us Bancorp \De\ transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 40,123 shares of ARWR stock, worth $787,614. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,123
Previous 45,110 11.06%
Holding current value
$787,614
Previous $1.17 Million 33.79%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$19.36 - $29.54 $96,548 - $147,315
-4,987 Reduced 11.06%
40,123 $776,000
Q2 2024

Aug 06, 2024

BUY
$21.87 - $28.24 $28,737 - $37,107
1,314 Added 3.0%
45,110 $1.17 Million
Q1 2024

May 07, 2024

SELL
$27.21 - $39.48 $65,548 - $95,107
-2,409 Reduced 5.21%
43,796 $1.25 Million
Q4 2023

Feb 09, 2024

SELL
$21.2 - $31.03 $20,118 - $29,447
-949 Reduced 2.01%
46,205 $1.41 Million
Q3 2023

Nov 03, 2023

BUY
$26.2 - $36.08 $31,964 - $44,017
1,220 Added 2.66%
47,154 $1.27 Million
Q2 2023

Aug 09, 2023

BUY
$25.16 - $41.38 $80,285 - $132,043
3,191 Added 7.47%
45,934 $1.64 Million
Q1 2023

May 09, 2023

BUY
$23.68 - $38.51 $586,814 - $954,316
24,781 Added 137.96%
42,743 $1.09 Million
Q4 2022

Feb 13, 2023

SELL
$28.0 - $40.56 $123,200 - $178,464
-4,400 Reduced 19.68%
17,962 $728,000
Q3 2022

Oct 27, 2022

BUY
$29.63 - $48.31 $186,431 - $303,966
6,292 Added 39.15%
22,362 $740,000
Q2 2022

Aug 01, 2022

SELL
$27.79 - $50.61 $37,460 - $68,222
-1,348 Reduced 7.74%
16,070 $566,000
Q1 2022

May 11, 2022

BUY
$39.62 - $69.97 $42,353 - $74,797
1,069 Added 6.54%
17,418 $801,000
Q4 2021

Feb 11, 2022

BUY
$58.09 - $82.51 $92,363 - $131,190
1,590 Added 10.77%
16,349 $1.08 Million
Q3 2021

Nov 10, 2021

BUY
$58.38 - $84.96 $66,553 - $96,854
1,140 Added 8.37%
14,759 $922,000
Q2 2021

Aug 05, 2021

BUY
$62.15 - $90.32 $63,641 - $92,487
1,024 Added 8.13%
13,619 $1.13 Million
Q1 2021

Apr 28, 2021

BUY
$61.35 - $90.47 $496,137 - $731,630
8,087 Added 179.39%
12,595 $836,000
Q4 2020

Feb 04, 2021

BUY
$43.82 - $85.37 $2,366 - $4,609
54 Added 1.21%
4,508 $346,000
Q3 2020

Nov 10, 2020

SELL
$33.21 - $51.27 $6,874 - $10,612
-207 Reduced 4.44%
4,454 $191,000
Q2 2020

Aug 07, 2020

SELL
$26.12 - $43.27 $4,701 - $7,788
-180 Reduced 3.72%
4,661 $201,000
Q1 2020

May 13, 2020

SELL
$20.56 - $63.12 $5,489 - $16,853
-267 Reduced 5.23%
4,841 $139,000
Q4 2019

Feb 04, 2020

BUY
$28.14 - $73.01 $7,822 - $20,296
278 Added 5.76%
5,108 $324,000
Q3 2019

Nov 08, 2019

BUY
$26.26 - $34.86 $5,829 - $7,738
222 Added 4.82%
4,830 $136,000
Q2 2019

Aug 13, 2019

BUY
$17.43 - $28.82 $2,126 - $3,516
122 Added 2.72%
4,608 $123,000
Q1 2019

May 08, 2019

SELL
$12.05 - $20.18 $3,193 - $5,347
-265 Reduced 5.58%
4,486 $82,000
Q4 2018

Feb 13, 2019

BUY
$10.74 - $19.7 $51,025 - $93,594
4,751 New
4,751 $59,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.